Global Inflammatory Bowel Disease Treatment Market Set to Soar with Predicted 5.84% CAGR by 2034
January 29, 2024 05:04 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. ...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
December 27, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Artificial Intelligence (AI) in Inflammatory Bowel Disease Market Size, Growth, Demand, Trends, Report By 2032
December 15, 2023 10:00 ET
|
Precedence Research
Ottawa, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The global artificial intelligence (AI) in inflammatory bowel disease market is expected to expand at a remarkable CAGR during the forecast period 2023 to...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023 16:48 ET
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: ...
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
November 09, 2023 07:35 ET
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Asia-Pacific Anti-inflammatory Therapeutics Market to Reach $40.5 Billion by 2032 With CAGR of 5.4%: Says Allied Market Research
November 05, 2023 18:55 ET
|
Allied Market Research
Wilmington, Delaware, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Asia-Pacific Anti-inflammatory Therapeutics Market, By Drug Class (Biologics, NSAIDs,...